Kazia Therapeutics study of paxalisib in primary CNS Lymphoma at Dana-Farber enrols first patient
Kazia Therapeutics Ltds (ASX:KZA) (FRA:NV9M) (NASDAQ:KZIA) phase-II study of paxalisib in Primary CNS Lymphoma has been initiated at Dana-Farber Cancer Institute in Boston, Massachusetts, with the first patient enrolled to the study. Lymphoma is a cancer of white blood cells that occurs in the lymphatic system and can spread almost anywhere in the body while primary CNS lymphoma (PCNSL) occurs exclusively in the brain and central nervous system. The PI3K inhibitor class, to which paxalisib belongs, is well validated in lymphoma outside the brain
Kazia Therapeutics study of paxalisib in primary CNS Lymphoma at Dana-Farber enrols first patient
Kazia Therapeutics Ltds (ASX:KZA) (FRA:NV9M) (NASDAQ:KZIA) phase-II study of paxalisib in Primary CNS Lymphoma has been initiated at Dana-Farber Cancer Institute in Boston, Massachusetts, with the first patient enrolled to the study. Lymphoma is a cancer of white blood cells that occurs in the lymphatic system and can spread almost anywhere in the body while primary CNS lymphoma (PCNSL) occurs exclusively in the brain and central nervous system. The PI3K inhibitor class, to which paxalisib belongs, is well validated in lymphoma outside the brain